Cargando…
DoE-Assisted Development of a Novel Glycosaminoglycan-Based Injectable Formulation for Viscosupplementation
The aim of the present work was the development of a novel glycosaminoglycan (GAG)-based injectable formulation intended for intra-articular administration that should best mimic the healthy synovial fluid. Hyaluronic acid (HA) was chosen among GAG polymers, since it is the most abundant component o...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407620/ https://www.ncbi.nlm.nih.gov/pubmed/32698313 http://dx.doi.org/10.3390/pharmaceutics12070681 |
_version_ | 1783567663550693376 |
---|---|
author | Cicognani, Marta Rossi, Silvia Vecchi, Gabriele Giori, Andrea Maria Ferrari, Franca |
author_facet | Cicognani, Marta Rossi, Silvia Vecchi, Gabriele Giori, Andrea Maria Ferrari, Franca |
author_sort | Cicognani, Marta |
collection | PubMed |
description | The aim of the present work was the development of a novel glycosaminoglycan (GAG)-based injectable formulation intended for intra-articular administration that should best mimic the healthy synovial fluid. Hyaluronic acid (HA) was chosen among GAG polymers, since it is the most abundant component of the synovial fluid. A DoE (Design of Experiment) approach was used for the development of a formulation containing two HA (very high (VHMW) and low (LMW) molecular weight) grades. The rationale for this choice is that so far, no commercial product based on a single HA grade or even on binary HA mixture possesses optimal viscoelastic properties in comparison with healthy synovial fluid. A full factorial design was chosen to investigate the influence of concentration and relative fraction of the two polymer grades (retained as factors of the model) on formulation functional (viscosity and viscoelastic) properties, which are considered response variables. Thanks to the DoE approach, the composition of the optimized HA formulation was found. The addition to such formulation of an injectable grade fat-free soy phospholipid, which was rich in phosphatidylcholine (PC), resulted in improved lubrication properties. The final HA + PC formulation, packaged in pre-filled sterile syringes, was stable in long-term and accelerated ICH (International Council for Harmonisation) storage conditions. The overall results pointed out the formulation suitability for further steps of pharmaceutical developments, namely for the passage to pilot scale. |
format | Online Article Text |
id | pubmed-7407620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74076202020-08-12 DoE-Assisted Development of a Novel Glycosaminoglycan-Based Injectable Formulation for Viscosupplementation Cicognani, Marta Rossi, Silvia Vecchi, Gabriele Giori, Andrea Maria Ferrari, Franca Pharmaceutics Article The aim of the present work was the development of a novel glycosaminoglycan (GAG)-based injectable formulation intended for intra-articular administration that should best mimic the healthy synovial fluid. Hyaluronic acid (HA) was chosen among GAG polymers, since it is the most abundant component of the synovial fluid. A DoE (Design of Experiment) approach was used for the development of a formulation containing two HA (very high (VHMW) and low (LMW) molecular weight) grades. The rationale for this choice is that so far, no commercial product based on a single HA grade or even on binary HA mixture possesses optimal viscoelastic properties in comparison with healthy synovial fluid. A full factorial design was chosen to investigate the influence of concentration and relative fraction of the two polymer grades (retained as factors of the model) on formulation functional (viscosity and viscoelastic) properties, which are considered response variables. Thanks to the DoE approach, the composition of the optimized HA formulation was found. The addition to such formulation of an injectable grade fat-free soy phospholipid, which was rich in phosphatidylcholine (PC), resulted in improved lubrication properties. The final HA + PC formulation, packaged in pre-filled sterile syringes, was stable in long-term and accelerated ICH (International Council for Harmonisation) storage conditions. The overall results pointed out the formulation suitability for further steps of pharmaceutical developments, namely for the passage to pilot scale. MDPI 2020-07-20 /pmc/articles/PMC7407620/ /pubmed/32698313 http://dx.doi.org/10.3390/pharmaceutics12070681 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cicognani, Marta Rossi, Silvia Vecchi, Gabriele Giori, Andrea Maria Ferrari, Franca DoE-Assisted Development of a Novel Glycosaminoglycan-Based Injectable Formulation for Viscosupplementation |
title | DoE-Assisted Development of a Novel Glycosaminoglycan-Based Injectable Formulation for Viscosupplementation |
title_full | DoE-Assisted Development of a Novel Glycosaminoglycan-Based Injectable Formulation for Viscosupplementation |
title_fullStr | DoE-Assisted Development of a Novel Glycosaminoglycan-Based Injectable Formulation for Viscosupplementation |
title_full_unstemmed | DoE-Assisted Development of a Novel Glycosaminoglycan-Based Injectable Formulation for Viscosupplementation |
title_short | DoE-Assisted Development of a Novel Glycosaminoglycan-Based Injectable Formulation for Viscosupplementation |
title_sort | doe-assisted development of a novel glycosaminoglycan-based injectable formulation for viscosupplementation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407620/ https://www.ncbi.nlm.nih.gov/pubmed/32698313 http://dx.doi.org/10.3390/pharmaceutics12070681 |
work_keys_str_mv | AT cicognanimarta doeassisteddevelopmentofanovelglycosaminoglycanbasedinjectableformulationforviscosupplementation AT rossisilvia doeassisteddevelopmentofanovelglycosaminoglycanbasedinjectableformulationforviscosupplementation AT vecchigabriele doeassisteddevelopmentofanovelglycosaminoglycanbasedinjectableformulationforviscosupplementation AT gioriandreamaria doeassisteddevelopmentofanovelglycosaminoglycanbasedinjectableformulationforviscosupplementation AT ferrarifranca doeassisteddevelopmentofanovelglycosaminoglycanbasedinjectableformulationforviscosupplementation |